Aktuellt
SENASTE
Redeye returns with more insights on the Q3 report, and we continue to feel confident in OssDsign’s capabilities in increasing Catalyst sales in the coming quarters. We also highlight next year’s clinical data publications as share price drivers. Following the report, we make no particular changes to our estimates or valuation.
LÄS MER
